CYP2D6 genotype and associated 5‐ HT 3 receptor antagonist outcomes: A systematic review and meta‐analysis

Abstract 5‐hydroxytryptamine‐3 (5‐HT 3 ) receptor antagonists including ondansetron, tropisetron, dolasetron, palonosetron, granisetron, and ramosetron are commonly used to prevent and treat nausea and vomiting. Most of these medications are at least partially metabolized via the highly polymorphic CYP2D6 enzyme, resulting in variations of metabolism among individuals. Current (2017) international prescribing guidelines for ondansetron/tropisetron use according to genotype provide recommendations for CYP2D6 ultrarapid metabolizers but not intermediate or poor metabolizers. However, multiple studies have been conducted since this guideline was published. This review evaluated all available evidence of an association between CYP2D6 genotype and 5‐HT 3 receptor antagonist outcomes, including in patients who are CYP2D6 intermediate/poor metabolizers and pediatric‐specific studies. In this review, we confirm that CYP2D6 genotype impacts ondansetron response in a postoperative nausea and vomiting setting, which was supported by a meta‐analysis. We also highlight the heterogeneity and limitations of included studies as well as provide future directions for pharmacogenomics research.